BIOLASE (BIOL) Set to Announce Earnings on Monday

BIOLASE (NASDAQ:BIOL) will be posting its quarterly earnings results after the market closes on Monday, May 13th. BIOLASE has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.

BIOLASE (NASDAQ:BIOL) last released its quarterly earnings data on Thursday, March 21st. The medical technology company reported ($1.76) EPS for the quarter. The company had revenue of $13.49 million for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%.

BIOLASE Price Performance

BIOL traded down $0.01 during midday trading on Tuesday, reaching $0.17. 550,668 shares of the company’s stock were exchanged, compared to its average volume of 4,195,461. The company has a debt-to-equity ratio of 34.06, a current ratio of 1.26 and a quick ratio of 0.68. The business’s 50-day moving average price is $0.15 and its 200 day moving average price is $0.73. BIOLASE has a 1-year low of $0.13 and a 1-year high of $32.09. The stock has a market capitalization of $5.64 million, a PE ratio of -0.01 and a beta of 0.71.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on BIOLASE in a research note on Saturday. They issued a “sell” rating for the company.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.